Skip to main content
. 2018 Apr 10;2(7):807–816. doi: 10.1182/bloodadvances.2017015164

Table 1.

Patient characteristics according to TMTV and circulating parameters

Patients with TMTV, n = 133 TMTV > 510, n = 50/133 Patients with cfDNA analyses, n = 61 Patients with cfDNA > 2550, n = 37/61 Patients with evaluable* CTCs, n = 68 Patients with CTCs > 0.0018, n = 42/68
n (missing) % n (missing) % n (missing) % n (missing) % n (missing) % n (missing) %
Median age (range), y 60 (28-75) 61 (31-77) 62 (34-77) 64 (41-77) 59 (33-75) 58 (33-75)
Age >60 y 64 48 26 52 33 54 23 62 28 41 17 40
Female sex 68 51 22 44 32 52 16 43 33 49 17 40
Ann Arbor stage III-IV 126 95 50 100 58 95 36 97 67 99 42 100
No. of involved areas >4 83 (3) 64 42 (2) 87 46 75 32 86 44 65 32 76
Bone marrow biopsy (+) 78 (5) 61 40 (1) 81 39 (1) 65 26 (1) 72 41 (3) 63 36 (1) 88
LodLIN (cm) >6 47 (5) 37 20 40 19 31 13 35 20 (1) 30 13 (1) 32
LDH >Nl 20 15 09 18 13 21 10 27 11 16 8 19
β2-microglobulin >Nl 68 (13) 57 38 (4) 83 35 57 27 73 33 (12) 59 26 (6) 72
FLIPI score 3-4 61 46 31 62 34 56 25 68* 31 46 20 48
FLIPI2 score 3-4 55 (6) 43 30 (2) 62* 28 (1) 47 23 (1) 64* 28 (5) 44 21 (2) 52
Median SUVmax (range) 8.8 (2.4-27.6) 8.36 (3.41-27.6) 9.63 (2.4-21.8) 10.6 (2.38-18.3) 9.0 (4.99-27.6) 8.31 (4.99-27.6)
Median TMTV, cm3 (range) 354 (14-7796) 855 (520-7796) 392 (17-7795) 724 (17-7795) 413 (32-3432) 658 (32-3432)
First-line treatment
 R chemo 48 36 19 38 17 28 9 24 23 34 13 31
 R chemo + M 60 45 19 38 29 47 16 43 27 40 18 43
 Chemo-free§ 4 3 2 3 1 3 1 1
 Chemo-free§ + M 21 16 12 24 13 21 11 30 17 25 11 26

Chi-squared comparison of parameters between patients with high levels and total analyzed population. Values are “n (missing)” and “%” of patients except as noted.

LDH, lactate dehydrogenase; M, Revlimid maintenance; R, Revlimid.

*

P < .05.

P < .01.

R chemo: PRIMA-like R-CHOP R (6 cycles of R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone] plus 2 cycles of rituximab): n = 84. R2-CHOP (addition of lenalidomide [Revlimid; Celgene] to the R-CHOP regimen): n = 15. Other R-chemo schedule: n = 9.

§

Chemo-free: R2 (oral lenalidomide 20 mg for 21 days in a 28-day cycle, with rituximab 375 mg/m2 given intravenously on day 1 of each cycle for at least 6 cycles): n = 23; Revlimid alone (n = 2).